STOCK TITAN

Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Outlook Therapeutics, a pre-commercial biopharmaceutical company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company is focused on developing ONS-5010/LYTENAVA™, an investigational therapy aimed at being the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. The presentation will be led by Lawrence Kenyon, Chief Financial Officer, with opportunities for one-on-one meetings with investors. A video webcast of the presentation will be available on May 24, 2022.

Positive
  • None.
Negative
  • None.

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD under the PHSA 351(a) regulatory pathway. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com


FAQ

What will Outlook Therapeutics present at the H.C. Wainwright Global Investment Conference 2022?

Outlook Therapeutics will present information about their investigational therapy ONS-5010/LYTENAVA™, aimed at being the first FDA-approved ophthalmic formulation of bevacizumab.

When is the H.C. Wainwright Global Investment Conference taking place?

The conference will be held from May 23-26, 2022.

Who is presenting for Outlook Therapeutics at the conference?

Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present.

How can interested investors access the presentation from Outlook Therapeutics?

The presentation will be accessible via a video webcast starting May 24, 2022, at 7:00 AM ET.

What is the significance of ONS-5010/LYTENAVA™ for Outlook Therapeutics?

ONS-5010/LYTENAVA™ is intended to be the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases.

Outlook Therapeutics, Inc.

NASDAQ:OTLK

OTLK Rankings

OTLK Latest News

OTLK Stock Data

32.53M
15.23M
35.58%
35.65%
14.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ISELIN